News of the day
Depomed Reports Results From Two Phase 3 Clinical Trials Evaluating Non-Hormonal Therapy for Menopausal Hot Flashes
MENLO PARK, Calif., Oct 12, 2009 -- Depomed, Inc. (NASDAQ:DEPO) announced today top-line results from the BREEZE 1 and 2 Phase 3 clinical trials evaluating the safety and efficacy of SeradaTM, an investigational non-hormonal extended release formulation of gabapentin for the treatment of menopausal hot flashes.
more
Changed definition of safe contraception in clinical trials
Danish Medicines Agency, 2 October 2009--We have updated section 5.1 Contraception in the Guideline for applications for authorisation of clinical trials of medicinal products in humans.
more
Industry news search
Recent news
To keep up to date with news from this category use our 